JPWO2020056232A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056232A5 JPWO2020056232A5 JP2021514070A JP2021514070A JPWO2020056232A5 JP WO2020056232 A5 JPWO2020056232 A5 JP WO2020056232A5 JP 2021514070 A JP2021514070 A JP 2021514070A JP 2021514070 A JP2021514070 A JP 2021514070A JP WO2020056232 A5 JPWO2020056232 A5 JP WO2020056232A5
- Authority
- JP
- Japan
- Prior art keywords
- etv1
- erg
- combination
- pharmaceutical composition
- etv4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 238000009167 androgen deprivation therapy Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical group C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 3
- 229960000853 abiraterone Drugs 0.000 claims 3
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims 3
- 229950007511 apalutamide Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 3
- 229960004671 enzalutamide Drugs 0.000 claims 3
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- VUFGOHIETLJZRG-UHFFFAOYSA-N 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-methylimidazo[4,5-b]pyridin-2-amine Chemical compound C(C1=CC=CC=C1)N1C(=NC2=NC=C(C=C21)C=1C(=NOC=1C)C)NC VUFGOHIETLJZRG-UHFFFAOYSA-N 0.000 claims 1
- OEPMGQATBAQVFK-UHFFFAOYSA-N 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)imidazo[4,5-b]pyridin-2-amine Chemical compound C(C1=CC=CC=C1)N1C(=NC2=NC=C(C=C21)C=1C(=NOC=1C)C)N OEPMGQATBAQVFK-UHFFFAOYSA-N 0.000 claims 1
- 102100032959 Alpha-actinin-4 Human genes 0.000 claims 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 102100039563 ETS translocation variant 1 Human genes 0.000 claims 1
- 102100039577 ETS translocation variant 5 Human genes 0.000 claims 1
- 101000797282 Homo sapiens Alpha-actinin-4 Proteins 0.000 claims 1
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 claims 1
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 claims 1
- 101000910249 Homo sapiens Soluble calcium-activated nucleotidase 1 Proteins 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 108010018070 Proto-Oncogene Proteins c-ets Proteins 0.000 claims 1
- 102000004053 Proto-Oncogene Proteins c-ets Human genes 0.000 claims 1
- 102100024397 Soluble calcium-activated nucleotidase 1 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 239000003936 androgen receptor antagonist Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229950001379 darolutamide Drugs 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730869P | 2018-09-13 | 2018-09-13 | |
| US62/730,869 | 2018-09-13 | ||
| US201862737612P | 2018-09-27 | 2018-09-27 | |
| US62/737,612 | 2018-09-27 | ||
| US201862778185P | 2018-12-11 | 2018-12-11 | |
| US62/778,185 | 2018-12-11 | ||
| PCT/US2019/050970 WO2020056232A1 (fr) | 2018-09-13 | 2019-09-13 | Polythérapie pour le traitement du cancer de la prostate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500431A JP2022500431A (ja) | 2022-01-04 |
| JPWO2020056232A5 true JPWO2020056232A5 (fr) | 2022-09-22 |
| JP7441214B2 JP7441214B2 (ja) | 2024-02-29 |
Family
ID=69778254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514070A Active JP7441214B2 (ja) | 2018-09-13 | 2019-09-13 | 前立腺がんの治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117942A1 (fr) |
| EP (1) | EP3849544A4 (fr) |
| JP (1) | JP7441214B2 (fr) |
| KR (1) | KR20210060515A (fr) |
| CN (1) | CN112912075B (fr) |
| AU (1) | AU2019338483A1 (fr) |
| CA (1) | CA3112396A1 (fr) |
| IL (1) | IL281281A (fr) |
| MX (1) | MX2021002884A (fr) |
| SG (1) | SG11202102492PA (fr) |
| TW (1) | TWI816880B (fr) |
| WO (1) | WO2020056232A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117136057A (zh) * | 2021-02-22 | 2023-11-28 | 赛尔基因昆蒂赛尔研究公司 | 用于治疗前列腺癌的溴结构域(bet)抑制剂 |
| CN114644687B (zh) * | 2022-04-07 | 2023-06-27 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US20140057908A1 (en) * | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| CN109939113B (zh) * | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
| EP3062808B1 (fr) * | 2013-10-28 | 2021-09-29 | The Regents of the University of California | Traitement d'un cancer de la prostate métastasique |
| NO2719005T3 (fr) * | 2014-07-28 | 2018-01-20 | ||
| WO2016171470A1 (fr) * | 2015-04-21 | 2016-10-27 | Kainos Medicine, Inc. | Composés inhibiteurs de bromodomaine et méthodes pour prévenir ou traiter un cancer |
| US20190134004A1 (en) * | 2016-06-16 | 2019-05-09 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| US20180141939A1 (en) * | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| US20180153867A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
-
2019
- 2019-09-12 TW TW108133128A patent/TWI816880B/zh active
- 2019-09-13 JP JP2021514070A patent/JP7441214B2/ja active Active
- 2019-09-13 WO PCT/US2019/050970 patent/WO2020056232A1/fr unknown
- 2019-09-13 CN CN201980059904.2A patent/CN112912075B/zh active Active
- 2019-09-13 SG SG11202102492PA patent/SG11202102492PA/en unknown
- 2019-09-13 AU AU2019338483A patent/AU2019338483A1/en active Pending
- 2019-09-13 KR KR1020217010491A patent/KR20210060515A/ko unknown
- 2019-09-13 MX MX2021002884A patent/MX2021002884A/es unknown
- 2019-09-13 US US17/275,473 patent/US20220117942A1/en active Pending
- 2019-09-13 EP EP19860912.5A patent/EP3849544A4/fr active Pending
- 2019-09-13 CA CA3112396A patent/CA3112396A1/fr active Pending
-
2021
- 2021-03-04 IL IL281281A patent/IL281281A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020053655A5 (fr) | ||
| JP2020512350A (ja) | ニラパリブ組成物 | |
| JP2015512406A5 (fr) | ||
| JP2021152008A5 (fr) | ||
| KR20110045004A (ko) | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 | |
| JP2023175694A5 (fr) | ||
| JP2012521355A5 (fr) | ||
| JP2021073257A5 (fr) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| AU2015301097A1 (en) | Drug combinations to treat multiple myeloma | |
| JP2021509395A5 (fr) | ||
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| CA3080644A1 (fr) | Utilisation d'un inhibiteur de parp dans le traitement du cancer de l'ovaire resistant a la chimiotherapie ou du cancer du sein | |
| JP2011512370A (ja) | ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤 | |
| JP2005519893A5 (fr) | ||
| JP2019507786A5 (fr) | ||
| JPWO2020056232A5 (fr) | ||
| JP2019509309A5 (fr) | ||
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JP2011506607A5 (fr) | ||
| WO2017148129A1 (fr) | Composition pharmaceutique destinée au traitement de la cachexie et son utilisation | |
| JP2017530132A5 (fr) | ||
| WO2020238932A1 (fr) | Utilisation d'un inhibiteur de parp en combinaison avec un inhibiteur de vegfr pour traiter le cancer de l'ovaire ou le cancer du sein | |
| JP2014511850A5 (fr) | ||
| JP2023530253A (ja) | 併用療法 |